Business
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
Oakville, Ontario--(Newsfile Corp. - April 1, 2020) -  Cardiol Therapeutics Inc. ( TSX:...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart FailureData Accepted for Presentation at the American College of Cardiology Annual MeetingOakville, Ontario--(Newsfile Corp. - April 1, 2020) -  Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that data submitted by its international research collaborators were accepted for presentation at the American College of Cardiology's (ACC) 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually from March 28-30. All accepted abstracts will be subsequently published. The effects of Cardiol's pharmaceutically produced (cGMP) cannabidiol formulation were assessed in a model of non-ischemic heart failure. Heart failure was induced by four weeks of infusion of angiotensin II, a substance that produces hypertension, cardiac enlargement, and subsequent heart failure. Two dosages of Cardiol's cannabidiol formulation (or placebo) were administered by subcutaneous injection every three days for four weeks. In addition, the effects of CBD on angiotensin-induced hypertrophy (cell enlargement) and expression of B-type Natriuretic Peptide (BNP) in a cardiac cell line (H9c2) were assessed. BNP is a substance released from stretched heart cells which is a widely used clinical indicator of the severity of heart failure. The study found that Cardiol's cannabidiol formulation significantly reduced hypertrophy and produced a dose-dependent reduction of key inflammation markers, decreases in fibrosis, and lower BNP expression. These findings confirm the anti-inflammatory and anti-fibrotic activity of Cardiol's cannabidiol formulation in a model of heart failure. Moreover, the data show that cannabidiol reduced the amount of BNP released, thereby confirming the role of Cardiol's cannabidiol formulation as a cardioprotective therapy. Results from this study are supportive of the Company's plans for its Phase 2 international trial in acute myocarditis, an inflammatory form of heart failure that represents a leading cause of sudden cardiac death in children and young ad...